FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Hyperhomocysteinemia in patients with pulmonary embolism

Thumbnail
2010
1324.pdf (137.6Kb)
Authors
Radovanović, N.
Antonijević, N.
Beletić, Anđelo
Perunicić, J.
Kocica, Mladen J.
Mirković, Duško
Lacković, Vesna
Lacković, Milena
Article (Published version)
Metadata
Show full item record
Abstract
Investigation of hyperhomocysteinemia (HHcy) as an important risk factor for pulmonary thromboembolism (PTE), which represents a most dangerous consequence of a unique phenomenon of venous thromboembolism which still suffers from sometimes conflicting or inadequately clarified results. The role of homocysteine in the clinical manifestation of this life-threatening disease and its treatment (in which any further information may be decisive) requires detailed examination. The purpose of this study is to determine the differences in HHcy incidence and homocysteinemia levels between patients with PTE and healthy persons. The study enrolled 70 patients with PTE and 50 healthy persons. Homocysteine was measured using the HPLC method with fluorescent detection and HHcy was defined as homocysteinemia above 12 mu mol/L. Statistical analyses included chi-square and Mann Whitney U tests. The median homocysteinemia value was significantly higher (p=0.017) in the patients (12.10 mu mol/L) than in t...he controls (10.35 mu mol/L). The comparison of HHcy incidence between the patients (51.5%) and controls (30%) revealed a significant difference (p=0.021). In patients, homocysteinemia was significantly higher (p=0.002) in men (14.05 mu mol/L) than in women (10.01 mu mol/L) HHcy was present in 67.6% of men with PTE, which was significantly higher (p=0.006) than the incidence in women with PTE (33.3%). Healthy males had significantly higher (p=0.001) homocysteinemia (12.54 mu mol/L) than healthy females (9.4 mu mol/L). A significant difference (p=0.031) was observed between the incidences of HHcy in healthy males (44.0%) and healthy females (16.0%). We conclude that the incidence of hyperhomocysteinemia and homocysteinemia are significantly higher in all the patients compared with de healthy persons, as well as in both healthy males and males with PTE compared with healthy females and female patients. This indicates that HHcy findings in PE are likely to have a clinical importance.

Keywords:
Homocysteine / pulmonary embolism (PE)
Source:
Archives of Biological Sciences, 2010, 62, 4, 907-914
Publisher:
  • Srpsko biološko društvo, Beograd, i dr.
Funding / projects:
  • Cytohistological, immunohistochemical and clinical investigations of vascular remodeling in blood vessel diseases and angiogenesis (RS-145074)

DOI: 10.2298/ABS1004907R

ISSN: 0354-4664

WoS: 000287217500006

Scopus: 2-s2.0-78650981848
[ Google Scholar ]
2
2
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/1326
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Radovanović, N.
AU  - Antonijević, N.
AU  - Beletić, Anđelo
AU  - Perunicić, J.
AU  - Kocica, Mladen J.
AU  - Mirković, Duško
AU  - Lacković, Vesna
AU  - Lacković, Milena
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1326
AB  - Investigation of hyperhomocysteinemia (HHcy) as an important risk factor for pulmonary thromboembolism (PTE), which represents a most dangerous consequence of a unique phenomenon of venous thromboembolism which still suffers from sometimes conflicting or inadequately clarified results. The role of homocysteine in the clinical manifestation of this life-threatening disease and its treatment (in which any further information may be decisive) requires detailed examination. The purpose of this study is to determine the differences in HHcy incidence and homocysteinemia levels between patients with PTE and healthy persons. The study enrolled 70 patients with PTE and 50 healthy persons. Homocysteine was measured using the HPLC method with fluorescent detection and HHcy was defined as homocysteinemia above 12 mu mol/L. Statistical analyses included chi-square and Mann Whitney U tests. The median homocysteinemia value was significantly higher (p=0.017) in the patients (12.10 mu mol/L) than in the controls (10.35 mu mol/L). The comparison of HHcy incidence between the patients (51.5%) and controls (30%) revealed a significant difference (p=0.021). In patients, homocysteinemia was significantly higher (p=0.002) in men (14.05 mu mol/L) than in women (10.01 mu mol/L) HHcy was present in 67.6% of men with PTE, which was significantly higher (p=0.006) than the incidence in women with PTE (33.3%). Healthy males had significantly higher (p=0.001) homocysteinemia (12.54 mu mol/L) than healthy females (9.4 mu mol/L). A significant difference (p=0.031) was observed between the incidences of HHcy in healthy males (44.0%) and healthy females (16.0%). We conclude that the incidence of hyperhomocysteinemia and homocysteinemia are significantly higher in all the patients compared with de healthy persons, as well as in both healthy males and males with PTE compared with healthy females and female patients. This indicates that HHcy findings in PE are likely to have a clinical importance.
PB  - Srpsko biološko društvo, Beograd, i dr.
T2  - Archives of Biological Sciences
T1  - Hyperhomocysteinemia in patients with pulmonary embolism
VL  - 62
IS  - 4
SP  - 907
EP  - 914
DO  - 10.2298/ABS1004907R
UR  - conv_2394
ER  - 
@article{
author = "Radovanović, N. and Antonijević, N. and Beletić, Anđelo and Perunicić, J. and Kocica, Mladen J. and Mirković, Duško and Lacković, Vesna and Lacković, Milena",
year = "2010",
abstract = "Investigation of hyperhomocysteinemia (HHcy) as an important risk factor for pulmonary thromboembolism (PTE), which represents a most dangerous consequence of a unique phenomenon of venous thromboembolism which still suffers from sometimes conflicting or inadequately clarified results. The role of homocysteine in the clinical manifestation of this life-threatening disease and its treatment (in which any further information may be decisive) requires detailed examination. The purpose of this study is to determine the differences in HHcy incidence and homocysteinemia levels between patients with PTE and healthy persons. The study enrolled 70 patients with PTE and 50 healthy persons. Homocysteine was measured using the HPLC method with fluorescent detection and HHcy was defined as homocysteinemia above 12 mu mol/L. Statistical analyses included chi-square and Mann Whitney U tests. The median homocysteinemia value was significantly higher (p=0.017) in the patients (12.10 mu mol/L) than in the controls (10.35 mu mol/L). The comparison of HHcy incidence between the patients (51.5%) and controls (30%) revealed a significant difference (p=0.021). In patients, homocysteinemia was significantly higher (p=0.002) in men (14.05 mu mol/L) than in women (10.01 mu mol/L) HHcy was present in 67.6% of men with PTE, which was significantly higher (p=0.006) than the incidence in women with PTE (33.3%). Healthy males had significantly higher (p=0.001) homocysteinemia (12.54 mu mol/L) than healthy females (9.4 mu mol/L). A significant difference (p=0.031) was observed between the incidences of HHcy in healthy males (44.0%) and healthy females (16.0%). We conclude that the incidence of hyperhomocysteinemia and homocysteinemia are significantly higher in all the patients compared with de healthy persons, as well as in both healthy males and males with PTE compared with healthy females and female patients. This indicates that HHcy findings in PE are likely to have a clinical importance.",
publisher = "Srpsko biološko društvo, Beograd, i dr.",
journal = "Archives of Biological Sciences",
title = "Hyperhomocysteinemia in patients with pulmonary embolism",
volume = "62",
number = "4",
pages = "907-914",
doi = "10.2298/ABS1004907R",
url = "conv_2394"
}
Radovanović, N., Antonijević, N., Beletić, A., Perunicić, J., Kocica, M. J., Mirković, D., Lacković, V.,& Lacković, M.. (2010). Hyperhomocysteinemia in patients with pulmonary embolism. in Archives of Biological Sciences
Srpsko biološko društvo, Beograd, i dr.., 62(4), 907-914.
https://doi.org/10.2298/ABS1004907R
conv_2394
Radovanović N, Antonijević N, Beletić A, Perunicić J, Kocica MJ, Mirković D, Lacković V, Lacković M. Hyperhomocysteinemia in patients with pulmonary embolism. in Archives of Biological Sciences. 2010;62(4):907-914.
doi:10.2298/ABS1004907R
conv_2394 .
Radovanović, N., Antonijević, N., Beletić, Anđelo, Perunicić, J., Kocica, Mladen J., Mirković, Duško, Lacković, Vesna, Lacković, Milena, "Hyperhomocysteinemia in patients with pulmonary embolism" in Archives of Biological Sciences, 62, no. 4 (2010):907-914,
https://doi.org/10.2298/ABS1004907R .,
conv_2394 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutions/communitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB